{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Butrovich MA"],"funding":["NCATS NIH HHS","National Cancer Institute","NCI NIH HHS","National Institutes of Health"],"pagination":["216679"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10939791"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["586"],"pubmed_abstract":["Cancer and kidney disease disproportionately impact Black patients. The CKD-EPI<sub>2021</sub> equation was developed to estimate glomerular filtration rate (eGFR) without using race. We assessed the impact of using CKD-EPI<sub>2021</sub> instead of CKD-EPI<sub>2009</sub> or Cockcroft-Gault (CG) on dosing and eligibility of anticancer drugs in Black and non-Black patients. Utilizing the National Cancer Institute Theradex database, deindexed eGFR (mL/min) was calculated for 3931 patients (8.6 % Black) using CKD-EPI<sub>2021</sub>, CKD-EPI<sub>2009</sub>, and CG. Dosing simulations based on each eGFR were performed for ten anticancer drugs with kidney function-based eligibility or dosing cutoffs. eGFR differences using CKD-EPI<sub>2021</sub> versus CKD-EPI<sub>2009</sub> varied between Black and non-Black patients (p < 0.001); on average, Black patients had 10.3 mL/min lower eGFR and non-Black patients had 4.2 mL/min higher eGFR using CKD-EPI<sub>2021</sub>. This corresponded to a difference in relative odds of cisplatin ineligibility using CKD-EPI<sub>2021</sub> versus CKD-EPI<sub>2009</sub>; Black patients had 48 % higher odds of ineligibility and non-Black patients had 27 % lower odds of ineligibility using CKD-EPI<sub>2021</sub> (p < 0.001). When using CKD-EPI<sub>2021</sub> versus CG, eGFR differences were similar between Black and non-Black patients (p = 0.679) and relative difference in odds of cisplatin ineligibility did not vary. Using CKD-EPI<sub>2021</sub> versus CKD-EPI<sub>2009</sub> differentially impacts Black versus non-Black cancer patients; Black patients have lower calculated eGFR and are less likely to receive full doses of drug using CKD-EPI<sub>2021</sub>. From the historical default of CG, adopting CKD-EPI<sub>2021</sub> would not disparately impact patients based on race, but would result in Black patients being less likely to receive full doses of drug than if CKD-EPI<sub>2009</sub> were used."],"journal":["Cancer letters"],"pubmed_title":["Impact of the 2021 CKD-EPI equation on anticancer pharmacotherapy in black and non-black cancer patients."],"pmcid":["PMC10939791"],"funding_grant_id":["P30 CA013330","UM1 CA186690","P30 CA047904","N02CM37106","NO2-CM37106","UM1CA186690","U24 CA247643","UM1 TR004400","P30CA013330","P30CA47904","U24CA247643"],"pubmed_authors":["Nolin TD","Qin J","Ivy SP","Butrovich MA","Xue X","Beumer JH"],"additional_accession":[]},"is_claimable":false,"name":"Impact of the 2021 CKD-EPI equation on anticancer pharmacotherapy in black and non-black cancer patients.","description":"Cancer and kidney disease disproportionately impact Black patients. The CKD-EPI<sub>2021</sub> equation was developed to estimate glomerular filtration rate (eGFR) without using race. We assessed the impact of using CKD-EPI<sub>2021</sub> instead of CKD-EPI<sub>2009</sub> or Cockcroft-Gault (CG) on dosing and eligibility of anticancer drugs in Black and non-Black patients. Utilizing the National Cancer Institute Theradex database, deindexed eGFR (mL/min) was calculated for 3931 patients (8.6 % Black) using CKD-EPI<sub>2021</sub>, CKD-EPI<sub>2009</sub>, and CG. Dosing simulations based on each eGFR were performed for ten anticancer drugs with kidney function-based eligibility or dosing cutoffs. eGFR differences using CKD-EPI<sub>2021</sub> versus CKD-EPI<sub>2009</sub> varied between Black and non-Black patients (p < 0.001); on average, Black patients had 10.3 mL/min lower eGFR and non-Black patients had 4.2 mL/min higher eGFR using CKD-EPI<sub>2021</sub>. This corresponded to a difference in relative odds of cisplatin ineligibility using CKD-EPI<sub>2021</sub> versus CKD-EPI<sub>2009</sub>; Black patients had 48 % higher odds of ineligibility and non-Black patients had 27 % lower odds of ineligibility using CKD-EPI<sub>2021</sub> (p < 0.001). When using CKD-EPI<sub>2021</sub> versus CG, eGFR differences were similar between Black and non-Black patients (p = 0.679) and relative difference in odds of cisplatin ineligibility did not vary. Using CKD-EPI<sub>2021</sub> versus CKD-EPI<sub>2009</sub> differentially impacts Black versus non-Black cancer patients; Black patients have lower calculated eGFR and are less likely to receive full doses of drug using CKD-EPI<sub>2021</sub>. From the historical default of CG, adopting CKD-EPI<sub>2021</sub> would not disparately impact patients based on race, but would result in Black patients being less likely to receive full doses of drug than if CKD-EPI<sub>2009</sub> were used.","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Apr","modification":"2025-06-28T03:05:10.715Z","creation":"2025-06-28T03:05:10.715Z"},"accession":"S-EPMC10939791","cross_references":{"pubmed":["38307411"],"doi":["10.1016/j.canlet.2024.216679"]}}